Core Insights - Molecular Partners AG is advancing its Radio-DARPin candidates, which are designed for targeted alpha therapy, and will present new preclinical data at the 3rd Global Radiopharmaceuticals Development Summit in Shanghai on March 19-20, 2026 [1][2] Group 1: Radio-DARPin Candidates - The presentation will highlight the suitability of Radio-DARPin candidates for different isotopes, showcasing two candidates with comparable biodistribution profiles when labeled with Lutetium-177 (Lu) or Lead-203 (Pb) [2] - Studies in tumor-bearing mice indicate similar uptake and washout rates for both Radio-DARPin candidates, suggesting that imaging with Lu can predict behavior with the therapeutic isotope Actinium-225 (Ac) [2] Group 2: Development Flexibility - The CEO of Molecular Partners stated that the Radio-DARPin design allows for the interchangeability of alpha-isotopes, providing flexibility to evaluate candidates in an isotope-agnostic manner [3] - This feature enables the selection of the most suitable therapeutic isotope based on initial clinical data without restarting the entire drug discovery process, which is a significant advantage for tailoring treatments to patient needs [3] Group 3: Clinical Trials and Collaborations - The DLL3-targeted Pb-based Radio-DARPin candidate MP0712 is currently in a Phase 1/2a trial in the US, with imaging data supporting its clinical development for small cell lung cancer and other DLL3-expressing neuroendocrine cancers [5] - In February 2026, Molecular Partners entered into an agreement with Eckert & Ziegler to support the development and manufacturing of Radio-DARPin therapeutics, covering activities for Radio-DARPins with Ac as the therapeutic payload and Lu as the imaging payload [6] Group 4: Technology and Innovation - Molecular Partners' Radio-DARPins are designed to deliver potent alpha-emitting isotopes to tumor lesions, addressing limitations of traditional radioligand therapy such as kidney accumulation and toxicity [7] - The proprietary Radio-DARPin platform enhances the delivery of radioactive payloads while preserving the advantages of small protein formats, thus unlocking a broad range of tumor targets for targeted radiopharmaceuticals [7] Group 5: Company Overview - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics for medical challenges that other treatment modalities cannot address, with proprietary programs in various stages of development [10]

Core Insights - Molecular Partners AG is advancing its Radio-DARPin candidates, which are designed for targeted alpha therapy, and will present new preclinical data at the 3rd Global Radiopharmaceuticals Development Summit in Shanghai [1][4] Group 1: Radio-DARPin Candidates - The presentation will highlight the suitability of Radio-DARPin candidates for different isotopes, showcasing two candidates with comparable biodistribution profiles when labeled with Lutetium-177 (177Lu) and Lead-203 (203Pb) [2] - Studies in tumor-bearing mice indicate similar uptake and washout rates for both Radio-DARPin candidates, suggesting that imaging with 177Lu can predict behavior with the therapeutic isotope Actinium-225 (225Ac) and similarly for 203Pb with 212Pb [2] Group 2: Development Flexibility - The CEO of Molecular Partners stated that the Radio-DARPin design allows for the interchangeability of alpha-isotopes, providing flexibility to evaluate candidates in an isotope-agnostic manner, which can be tailored to patient needs without restarting the drug development process [3] Group 3: Clinical Trials and Partnerships - The MP0712 candidate, which targets DLL3 and is co-developed with Orano Med, is currently in a Phase 1/2a trial in the US, with imaging data supporting its clinical development for small cell lung cancer and other DLL3-expressing neuroendocrine cancers [5] - In February 2026, Molecular Partners entered an agreement with Eckert & Ziegler to support the development and manufacturing of Radio-DARPin therapeutics, focusing on 225Ac as a therapeutic payload and 177Lu as an imaging payload [6] Group 4: Technology and Innovation - Molecular Partners' Radio-DARPins are designed to deliver potent alpha-emitting isotopes precisely to tumor lesions, addressing limitations of traditional radioligand therapy, such as kidney accumulation and toxicity [7] - The proprietary Radio-DARPin platform enhances the delivery of radioactive payloads while minimizing harm to healthy tissues, leveraging the unique properties of DARPins [9] Group 5: Company Overview - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics for challenging medical conditions, with proprietary programs in various stages of development and partnerships with leading pharmaceutical companies [10]

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present three posters at the American Association for Cancer Research (AACR) 2026 Annual Meeting, taking place April 17-22 in San Diego, California, USA. Details of the presentations at AACR 2026: ...

Disclaimer This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical ...

Initiated US Phase 1/2a study of DLL3-targeting 212Pb-based Radio-DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-developed with strategic partner Orano Med; initial data anticipated in 2026Second Radio-DARPin MP0726 targeting MSLN progressing towards first-in-human imaging; nomination of new Radio-DARPin candidates anticipated mid-2026Development agreement signed with leading radio-isotope specialist Eckert & Ziegler, enabling proprietary Radio-DARPin candidates with range of isotopes ...

Core Insights - Molecular Partners AG has presented promising first patient imaging and dosimetry data for its DLL3-targeted Radio-DARPin candidate MP0712 at the 8th Theranostics World Congress, indicating strong potential for treating small cell lung cancer and other DLL3-expressing neuroendocrine cancers [1][2][4] Clinical Development - The data from five evaluable patients show favorable tumor uptake of MP0712 with limited uptake in healthy tissues, supporting its therapeutic potential [2][3] - The biodistribution and dosimetry data validate the ongoing U.S. Phase 1/2a study of MP0712, which aims to assess safety and determine a recommended phase 2 dose [4][5] Presentation Details - Two posters and an oral presentation were made at the congress, highlighting the specific tumor accumulation and dosimetry data that support the clinical development of MP0712 [5][7] - The oral presentation titled "From DARPins to Radio-DARPin Therapeutics" was scheduled for January 31, 2026, focusing on the progress of MP0712 [7] Future Outlook - Initial clinical data from the Phase 1/2a study of MP0712 is expected in 2026, with the company planning to share safety and activity data as the study progresses [4][5] - The company aims to establish itself as a leader in alpha-targeted therapies for small cell lung cancer and neuroendocrine malignancies [4]

Core Insights - Molecular Partners AG has presented promising first patient imaging and dosimetry data for its DLL3-targeted Radio-DARPin candidate MP0712 at the 8th Theranostics World Congress, indicating strong potential for treating small cell lung cancer and other DLL3-expressing neuroendocrine cancers [1][2][4] Group 1: Clinical Development - The data from five evaluable patients support the clinical development plans for MP0712, which utilizes the therapeutic isotope 212Pb [2][4] - The biodistribution of MP0712 shows specific tumor uptake with limited accumulation in healthy tissues, reinforcing its therapeutic potential [3][4] - The ongoing Phase 1/2a study in the U.S. aims to assess safety and determine a recommended phase 2 dose for MP0712, with initial clinical data expected in 2026 [4][5] Group 2: Presentation Details - The data was presented through two posters and an oral presentation at the Theranostics World Congress, highlighting the favorable distribution profile and dosimetry data of MP0712 [2][5] - An oral presentation titled "From DARPins to Radio-DARPin Therapeutics" was conducted, showcasing the progress of MP0712 [7] Group 3: Company Strategy and Future Outlook - The CEO of Molecular Partners expressed optimism about the data, emphasizing the company's ambition to lead in alpha-targeted therapies for small cell lung cancer and neuroendocrine malignancies [4] - The company plans to share initial Phase 1 safety and activity data in 2026 as it advances its Radio-DARPin platform [4][5] - Molecular Partners' Radio-DARPins are designed to address limitations of traditional radioligand therapy, enhancing tumor uptake while minimizing toxicity [9][10]

Summary of Molecular Partners FY Conference Call Company Overview - **Company Name**: Molecular Partners (NasdaqGS:MOLN) - **Focus**: Development of DARPin candidates, particularly in the field of radiotherapy - **Financial Position**: Over $100 million in cash (approximately CHF 93 million) available for investment in R&D [4][30] Key Industry Insights - **Biotech Sector Outlook**: Increased confidence in a turnaround for the biotech sector in 2026, following a challenging period [3] - **Radiotherapy Market**: Positive feedback and renewed interest in radiotherapy, highlighted by the successful IPO of Aktis Oncology [3] Core Product Focus - **Primary Candidate**: MP0712, a DLL3-targeted DARPin, is expected to drive value creation in the upcoming year [4][6] - **Pipeline Overview**: Emphasis on MP0712, with additional focus on MPO 317 and MPO 533, which are also in development [6][11] Product Development and Clinical Trials - **MPO 317**: Initially considered a dead program, it has been revived due to promising phase one data showing immune activation in colorectal carcinoma. A new trial will involve 75 patients across 11 centers in France, with results expected in 2027 [10][11] - **MPO 533**: A multispecific DARPin targeting acute myeloid leukemia (AML), designed to eradicate residual disease clones. The focus will be on low disease burden patients [11][12] Radiotherapy Mechanism - **Mechanism of Action**: MP0712 utilizes a DARPin vector linked to a radioisotope (Lead-212) to target DLL3 in small cell lung cancer. The approach aims to combine the efficacy of T cell engagers with the durability of antibody-drug conjugates (ADCs) [14][16][18] - **Clinical Strategy**: The company plans to initiate a phase one dose escalation trial, starting with a 75-megabecquerel dose, with a fast-to-market strategy for small cell lung cancer [27][30] Safety and Efficacy Considerations - **Safety Profile**: The rapid decay of Lead-212 is expected to result in minimal hematological toxicity, with recovery of blood values anticipated [34][37] - **Patient Experience**: Radiotherapy is expected to offer a better quality of life for patients compared to T cell engagers, which often cause acute side effects [37] Partnerships and Collaborations - **Orano Med Partnership**: A 50/50 partnership focused on the supply of Lead-212, with Orano Med providing a robust supply chain and infrastructure for the isotope [40][43] - **Future Collaborations**: The company is open to exploring partnerships for other isotopes, such as actinium, to enhance treatment options [45][46] Future Directions - **Expansion of Indications**: Beyond small cell lung cancer, there are plans to explore other neuroendocrine tumors with DLL3 expression [47][48] - **Innovative Imaging Techniques**: The use of imaging agents to select patients with DLL3 expression is seen as pivotal for maximizing treatment efficacy [48] Conclusion - **Focus for 2026**: The primary focus will be on MP0712, with expectations for first-in-human results and safety data in the first half of the year, followed by activity data in the second half [30]

Company Overview - Molecular Partners is a clinical-stage biotech company founded in 2004, with operations and listings in Switzerland (SIX, 2014) and the US (Nasdaq, 2021)[12] - The company is financed with approximately USD 116 million / CHF 93 million to reach upcoming value inflection points[12] - Molecular Partners focuses on oncology with differentiated assets like MP0712 (targeted radiotherapy) and MP0533 (next-gen immune cell engagers)[12] Radio-DARPin Therapeutics (RDT) - The company is developing Radio-DARPin therapeutics, which are designed for precise delivery of potent radio-isotopes to tumors[26, 27] - Molecular Partners has a global partnership with Orano Med to develop 212Pb Radio-DARPin therapeutics, with a 50:50 cost and share split for 4 programs[33, 36] - MP0712, a 212Pb x DLL3 Radio-DARPin, is in Phase 1/2a clinical trials in the US for small cell lung cancer (SCLC) and other neuroendocrine cancers (NECs), with early data expected in 2026[43, 77] - Preclinical data for MP0712 shows high tumor accumulation (Tumor > Kidney) and reduction of established tumors in mice[51] - MP0726, a 212Pb x MSLN Radio-DARPin, is being developed for ovarian cancer and is progressing towards first-in-human (FIH) imaging[86, 94] Other Pipeline Programs - MP0317, a FAP-localized CD40 agonist, is in a Phase 2 combo study in advanced biliary tract cancer, with interim analysis expected by YE 2027[104, 117, 123] - MP0533, a tetra-specific T-cell engager for AML, is in Phase 1/2a, with decisional data expected in H1 2026[124] - The company is developing Switch-DARPin platform for next-generation T cell engagers, with a lead candidate selection expected in H1 2026 and an update at AACR 2026[99, 140] Financial Outlook - The company's cash of approximately USD 116 million (CHF 93 million) ensures funding until 2028[99]

Core Insights - Molecular Partners AG is advancing its clinical-stage pipeline of DARPin therapeutics, focusing on targeted radiotherapy and immune cell engagers, with significant milestones expected in 2026 [1][20]. Financial Overview - As of December 31, 2025, the company reported cash and cash equivalents of CHF 93.1 million, sufficient to fund operations until 2028 [3]. Clinical Development Updates - The Phase 1/2a trial for MP0712, a Radio-DARPin targeting DLL3 for small cell lung cancer (SCLC), has commenced, with initial patient dosing expected in Q1 2026 and initial clinical data anticipated in the same year [2][4][7]. - MP0726, another Radio-DARPin targeting mesothelin (MSLN) for ovarian cancer, is also in development, with preclinical data presented at the 2025 SNMMI meeting [6]. - An investigator-initiated Phase 2 trial for MP0317 in cholangiocarcinoma is ongoing, with the first patient treated in early 2026 [10][11]. - MP0533, a tetra-specific T cell engager for acute myeloid leukemia (AML), is in a Phase 1/2a trial, with updates on its clinical development expected in H1 2026 [12][14]. Scientific Advisory Board - The formation of a scientific advisory board, chaired by Prof. Ken Herrmann, aims to accelerate the development of targeted radiotherapeutics [8]. DARPin Technology - Molecular Partners' DARPin therapeutics are designed for high specificity and stability, enabling effective delivery of radioactive payloads to tumors while minimizing damage to healthy tissues [19].